Professor and Director of Neuro-Oncology Program
Neurology
Dr. Surasak Phuphanich, MD
Surasak Phuphanich is an expert in the field of Neurology. He went to University of Illinois College of Medicine at Chicago. University of Illinois College of Medicine at Chicago has a rank of 49 in research and a 85 in primary care He received awards:"America's Top Doctors", "Top's American Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Top Doctors:LA Area", "America's Top Doctors for Cancer", "Best Doctors", "Top Doctors:Southern California", "Atlanta Magazine: Top Doctors", "Top's American Physician Award", "Top Doctors for Southern California", "Tops American Oncologist Award", "Patients Choice Award", "Top Doctor in July Issue", "Tops American Physicians Award", "Americas Top Doctors for Cancer", "Recipient of NABTT Award for Best Quality of Data Management", "Georgia Cancer Coalition Distinguished Clinical Investigator Professorial Award", "Twenty Years of Continuous Service Award", "Recipient of NABTT Award for Best Quality of Data", "Recipient of NABTT Award for Best Accrual to Clinical Trial", "Scholar-Scientist Award", "Clinician, Scholar of the Year Award", "Dedicated Service Award", "Marquis Who's Who in the World", "Marquis Who's Who in the South and Southwest", "Neuro-Oncology Award", "Who's Who Among Rising Young Americans", "Special Award, Founding Physician", "Marquis Who's Who, Directory of Medical Specialists", "Research Fellowship Award", "Fellowship Award" and "National Scholastic Achievement Award". Surasak Phuphanich is a published doctor. He has 28 papers published. The most current publication "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma." Surasak Phuphanich is registered with Medicare and accepts Medicare payments.
Publications
- Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
- A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC).
- Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Gli...
- Retrospective Analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article.
- NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
- Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.
- Postpartum extracranial bilateral vertebral artery dissection mimicking subarachnoid hemorrhage.
- Phase I trial of sorafenib in patients with recurrent or progressive malignant Glioma.
- Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade Gliomas.
- Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
- A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade Gliomas.
- Phase 1 clinical trial of bortezomib in adults with recurrent malignant Glioma.
- DR5-mediated Disc controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas.
- Phase I Analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme.
- Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant Gliomas.
- Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant Glioma.
- Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma ce...
- A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, Lymphoma, or ...
- Neurologic improvement after high-dose intravenous immunoglobulin therapy in patients with paraneoplastic cerebellar degeneration associated with anti-Purkinje cell an...
- Treatment related myelitis in Hodgkin's Lymphoma following stem cell transplant, chemotherapy and radiation: a case report and review of the literature.
- The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride.
- Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma.
- Delivery Systems and molecular targets of mechanism-based therapies for GBM.
- Treatment of neoplastic meningitis: what is the standard of care?
- Oral sodium phenylbutyrate in patients with recurrent malignant Gliomas: a dose escalation and pharmacologic study.
- A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent mal...
- Emerging molecular therapies for Brain tumors.
Schools
Ramathibodi Hospital Faculty Of Medicine Mahidol University Faculty Of Medicine
St Francis Hospital Loyola University
University Ill Med Center Neurology
University Calif San Francisco NeuroOncology
Faculty Of Science Mahidol University
Procedures Preformed
- Biological Therapy
- EEG (Electroencephalogram)
- Immunotherapy
- Intrathecal Chemotherapy
- View All
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Ataxia
- Bell's Palsy
- View All
Doctors Specialties
Accepted Insurances
Awards
- America's Top Doctors
- Top's American Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Top Doctors:LA Area
- America's Top Doctors for Cancer
- Best Doctors
- Top Doctors:Southern California
- Atlanta Magazine: Top Doctors
- Top's American Physician Award
- Top Doctors for Southern California
- Tops American Oncologist Award
- Patients Choice Award
- Top Doctor in July Issue
- Tops American Physicians Award
- Americas Top Doctors for Cancer
- Recipient of NABTT Award for Best Quality of Data Management
- Georgia Cancer Coalition Distinguished Clinical Investigator Professorial Award
- Twenty Years of Continuous Service Award
- Recipient of NABTT Award for Best Quality of Data
- Recipient of NABTT Award for Best Accrual to Clinical Trial
- Scholar-Scientist Award
- Clinician, Scholar of the Year Award
- Dedicated Service Award
- Marquis Who's Who in the World
- Marquis Who's Who in the South and Southwest
- Neuro-Oncology Award
- Who's Who Among Rising Young Americans
- Special Award, Founding Physician
- Marquis Who's Who, Directory of Medical Specialists
- Research Fellowship Award
- Fellowship Award
- National Scholastic Achievement Award
Education
-
University of Illinois College of Medicine at Chicago
-
Mahidol University Faculty of Medicine
Hospital
-
Cedars-Sinai Medical Center
Drug Facts
| NPI NUMBER |
|
1457469074 |
| NPPES Provider LastName |
|
PHUPHANICH |
| NPPES Provider FirstName |
|
SURASAK |
| NPPES Provider ZIPCode |
|
90048 |
| NPPES Provider State |
|
CA |
| Specialty Description |
|
Nephrology |
| Total Claim Count |
|
78.0 |
| Distinct Opioid Count |
|
0.0 |
| Opioid Claim Count |
|
0.0 |
| Percent Opioid Claims |
|
0.0 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
| National Provider Identifier [NPI] |
1457469074 |
| Last Name Of The Provider |
PHUPHANICH |
| First Name Of The Provider |
SURASAK |
| View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog
This Doctor is OpenDoctor Recommended.
This doctor has more publications